Premium
Angio‐oedema in a Patient Treated with Etanercept for Rheumatoid Arthritis
Author(s) -
Sendur Omer Faruk,
Turan Yasemin,
Berkit Isil Karatas,
Tastaban Engin
Publication year - 2009
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2009.00401.x
Subject(s) - etanercept , medicine , rheumatoid arthritis , proinflammatory cytokine , context (archaeology) , tumor necrosis factor alpha , arthritis , antirheumatic agents , disease , necrosis , immunology , inflammation , paleontology , biology
In the treatment of rheumatoid arthritis, specific drugs targeting disease‐related proinflammatory cytokines such as tumour necrosis factor‐α have been observed to show a positive impact on the clinical course of the disease. One of these drugs, etanercept, is a recombinant soluble fusion protein of tumour necrosis factor‐α type 2 receptor. Although it has many well‐established side effects, up to date there has not been any report of angio‐oedema in the literature. Hence, we aimed to present clinical findings of a 59‐year‐old female patient who received etanercept for rheumatoid arthritis and developed angio‐oedema during treatment, and to the discuss side effects of the drug within the context of current literature.